U.S. FDA Approves Restylane Lyft for Enhancing the Chin Profile
The U.S. Food and Drug Administration (FDA) has approved Galderma’s Restylane Lyft with Lidocaine for augmentation of the chin region in patients aged 21 and up with mild-to-moderate chin retrusion.